Table 1 Baseline demography of study cohorts stratified by treatment indication.
Baseline patient-level demographics | ||||
|---|---|---|---|---|
DMO (N = 1600) | CRVO (N = 401) | BRVO (N = 741) | Overall (N = 2742) | |
Gender | ||||
Male | 965 (60.3%) | 224 (55.9%) | 368 (49.7%) | 1557 (56.8%) |
Female | 634 (39.6%) | 177 (44.1%) | 373 (50.3%) | 1184 (43.2%) |
Age at recruitment | ||||
Mean (SD) | 63 (11) | 68 (14) | 69 (12) | 65 (12) |
Median (IQR) | 63 (14) | 70 (19) | 69 (17) | 66 (16) |
Ethnicity | ||||
Afrocarribean | 173 (10.8%) | 29 (7.2%) | 73 (9.9%) | 275 (10.0%) |
Caucasian | 336 (21.0%) | 175 (43.6%) | 263 (35.5%) | 774 (28.2%) |
Chinese | 4 (0.3%) | 4 (1.0%) | 4 (0.5%) | 12 (0.4%) |
Mixed | 20 (1.3%) | 4 (1.0%) | 3 (0.4%) | 27 (1.0%) |
South-East Asian | 537 (33.6%) | 50 (12.5%) | 136 (18.4%) | 723 (26.4%) |
Unknown | 529 (33.1%) | 139 (34.7%) | 262 (35.4%) | 930 (33.9%) |
Index of multiple deprivation decile | ||||
1 | 52 (3.3%) | 18 (4.5%) | 14 (1.9%) | 84 (3.1%) |
2 | 273 (17.1%) | 48 (12.0%) | 77 (10.4%) | 398 (14.5) |
3 | 310 (19.4%) | 52 (13.0%) | 93 (12.6%) | 455 (16.6%) |
4 | 251 (15.7%) | 46 (11.5%) | 95 (12.8%) | 392 (14.3%) |
5 | 182 (11.4%) | 46 (11.5%) | 91 (12.3%) | 319 (11.6%) |
6 | 166 (10.4%) | 43 (10.7%) | 98 (13.2%) | 307 (11.2%) |
7 | 127 (7.9%) | 38 (9.5%) | 70 (9.4%) | 235 (8.6%) |
8 | 108 (6.8%) | 42 (10.5%) | 65 (8.8%) | 215 (7.8%) |
9 | 74 (4.6%) | 39 (9.7%) | 82 (11.1%) | 195 (7.1%) |
10 | 51 (3.2%) | 28 (7.0%) | 50 (6.7%) | 129 (4.7%) |
Null | 5 (0.3%) | 1 (0.2%) | 6 (0.8%) | 12 (0.4%) |
Missing | 1 (0.1%) | 0 (0.0%) | 0 (0.0%) | 1 (0.0%) |
